[go: up one dir, main page]

HN2011002834A - Inmunoconjugados de antimesotelina y usos de los mismos - Google Patents

Inmunoconjugados de antimesotelina y usos de los mismos

Info

Publication number
HN2011002834A
HN2011002834A HN2011002834A HN2011002834A HN2011002834A HN 2011002834 A HN2011002834 A HN 2011002834A HN 2011002834 A HN2011002834 A HN 2011002834A HN 2011002834 A HN2011002834 A HN 2011002834A HN 2011002834 A HN2011002834 A HN 2011002834A
Authority
HN
Honduras
Prior art keywords
othane
antibodies
immunoconjugados
mesotheline
othan
Prior art date
Application number
HN2011002834A
Other languages
English (en)
Inventor
Kerstin Berhorster
Iring Heisler
Charlotte Kopitz
Antije Kahnert
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HN2011002834A publication Critical patent/HN2011002834A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA INMUNOCONJUGADOS COMPUESTOS POR ANTICUERPOS, POR EJEMPLO ANTICUERPOS MONOCIONALES O FRAGMENTOS DE ANTICUERPO QUE SE UNEN A LA MESOTELINA, QUE ESTAN CONJUGADOS CON AGENTES CITOTOXICOS POR EJEMPLO MAITANSINA, O SUS DERIVADOS, Y/O SE CO-ADMINISTRAN O FORMULAN CON UNO O MAS AGENTES ANTICACEROSOS ADICIONALES. LOS INMUNOCONJUGADOS COMPRENDEN ANTICUERPOS Y FRAGMENTOS FUNCIONALES QUE CONTIENEN DICHAS REGIONES DE UNION AL ANTIGENO QUE SON ESPECIFICAS DEL POLIPEPTIDO DE MESOTELINA DE 40 KDA ANCLADO A LA MEMBRANA, QUE SE SOBREEXPRESA EN VARIOS TUMORES TALES COMO TUMORES PANCREATICOS Y OVARICOS MESOTELIOMA Y CELULAS DE CANCER DE PULMON.
HN2011002834A 2009-04-29 2011-10-27 Inmunoconjugados de antimesotelina y usos de los mismos HN2011002834A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09005909 2009-04-29

Publications (1)

Publication Number Publication Date
HN2011002834A true HN2011002834A (es) 2013-10-28

Family

ID=42332769

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011002834A HN2011002834A (es) 2009-04-29 2011-10-27 Inmunoconjugados de antimesotelina y usos de los mismos

Country Status (41)

Country Link
US (5) US9084829B2 (es)
EP (2) EP3292874B1 (es)
JP (3) JP5616433B2 (es)
KR (1) KR101681795B1 (es)
CN (2) CN102458477B (es)
AR (1) AR076284A1 (es)
AU (1) AU2010243942B2 (es)
BR (1) BRPI1014637B1 (es)
CA (1) CA2760114C (es)
CL (1) CL2011002681A1 (es)
CO (1) CO6450601A2 (es)
CR (1) CR20110566A (es)
CU (1) CU23929B1 (es)
CY (2) CY1119738T1 (es)
DK (2) DK2424569T3 (es)
DO (1) DOP2011000331A (es)
EC (1) ECSP11011423A (es)
ES (2) ES2790732T3 (es)
GT (1) GT201100269A (es)
HN (1) HN2011002834A (es)
HR (2) HRP20180015T1 (es)
HU (2) HUE037853T2 (es)
IL (1) IL215769A (es)
JO (1) JO3486B1 (es)
LT (2) LT3292874T (es)
MA (1) MA33229B1 (es)
MX (1) MX2011011365A (es)
MY (1) MY158624A (es)
NO (1) NO2424569T3 (es)
NZ (1) NZ596013A (es)
PE (1) PE20120556A1 (es)
PL (2) PL2424569T3 (es)
PT (2) PT2424569T (es)
SG (1) SG175254A1 (es)
SI (2) SI2424569T1 (es)
TN (1) TN2011000547A1 (es)
TW (2) TW201529084A (es)
UA (2) UA116874C2 (es)
UY (1) UY32560A (es)
WO (1) WO2010124797A1 (es)
ZA (1) ZA201107757B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
TWI589589B (zh) 2010-12-20 2017-07-01 建南德克公司 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
KR102103302B1 (ko) 2011-03-29 2020-04-23 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
SG193996A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
AU2013306076B2 (en) 2012-08-21 2018-01-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
WO2014043523A1 (en) * 2012-09-14 2014-03-20 The Johns Hopkins University Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing
ES2666131T3 (es) * 2012-09-27 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos de mesotelina y métodos para provocar una potente actividad antitumoral
EP2904089A4 (en) 2012-10-04 2016-05-25 Immunogen Inc USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES
HRP20191053T1 (hr) * 2013-10-25 2019-09-20 Bayer Pharma Aktiengesellschaft Nova stabilna formulacija
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
WO2015200773A1 (en) * 2014-06-27 2015-12-30 Oregon Health & Science University Compounds that bind dystroglycan and uses thereof
ES2944885T3 (es) * 2014-08-29 2023-06-26 Corium Pharma Solutions Inc Matriz de microestructuras para administración de agentes activos
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
NZ740855A (en) * 2015-08-21 2022-04-29 Crage Medical Co Ltd Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MA47022A (fr) 2016-02-05 2018-12-12 Immunogen Inc Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
WO2018048975A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
KR101966362B1 (ko) 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
EP3807321A4 (en) * 2018-06-18 2022-03-02 Anwita Biosciences, Inc. ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
TWI861005B (zh) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
TWI847989B (zh) 2018-07-12 2024-07-11 英商Ｆ—星治療有限公司 結合cd137及ox40的抗體分子
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP7458981B2 (ja) 2018-08-06 2024-04-01 第一三共株式会社 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
EP4222167A1 (en) 2020-09-30 2023-08-09 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
KR20230121560A (ko) 2022-02-10 2023-08-18 경북대학교 산학협력단 메소세린에 결합하는 펩타이드 및 이의 용도
IL318578A (en) 2022-08-02 2025-03-01 Nona Biosciences Suzhou Co Ltd Msln antibody-drug conjugate
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1437180A (en) 1920-12-16 1922-11-28 Wahl Co Mechanical pencil
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
CA2093022C (en) 1990-10-05 2005-02-22 Michael W. Fanger Targeted immunostimulation with bispecific reagents
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5773280A (en) 1992-03-20 1998-06-30 The Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
DE69214709T2 (de) 1991-04-26 1997-02-20 Surface Active Ltd Neue Antikörper und Verfahren zu ihrer Verwendung
US5407653A (en) 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
JPH0699141A (ja) * 1992-09-21 1994-04-12 Kubota Corp 石抜装置
JPH06124641A (ja) * 1992-10-08 1994-05-06 Mitsubishi Electric Corp 回路遮断器
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6294353B1 (en) 1994-10-20 2001-09-25 Morphosys Ag Targeted hetero-association of recombinant proteins to multi-functional complexes
JPH0945957A (ja) * 1995-07-28 1997-02-14 Oki Electric Ind Co Ltd 端面発光型ｌｅｄアレイの製造方法及びその検査方法
JP3724015B2 (ja) * 1995-08-08 2005-12-07 コベルコ建機株式会社 パイロット切換弁の応答性可変装置
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
ATE254931T1 (de) 1996-01-05 2003-12-15 Us Gov Health & Human Serv Mesothelinantigen, verfahren und testsatz zur targetierung
US7375183B1 (en) * 1996-01-05 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
JP2001522833A (ja) 1997-11-10 2001-11-20 ジー・ディー・サール・アンド・カンパニー 多剤耐性を治療するためのアルキル化イミノ糖類の使用
AU760120B2 (en) * 1997-12-01 2003-05-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
ES2269105T3 (es) 1999-02-26 2007-04-01 Pacific Northwest Research Institute Metodos y composiciones para el diagnostico de carcinomas.
EP1133565B1 (en) 1999-07-02 2010-09-22 MorphoSys AG Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP4829454B2 (ja) 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
AU2003247686A1 (en) 2002-07-02 2004-01-23 Smithkline Beecham Corporation A novel stable formulation
CA2737127C (en) 2003-05-14 2016-07-26 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
DE60325906D1 (de) 2003-08-08 2009-03-05 Amgen Fremont Inc Antikörper gegen parath-hormon (pth) und ihre verwendungen
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
CN1993146A (zh) * 2004-06-01 2007-07-04 健泰科生物技术公司 抗体－药物偶联物和方法
EP1753463A2 (en) 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
WO2006086733A2 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
ES2386367T3 (es) * 2005-03-10 2012-08-17 Morphotek, Inc. Anticuerpos anti-mesotelina
AU2006247565A1 (en) * 2005-05-12 2006-11-23 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anti-mesothelin antibodies useful for immunological assays
PT3620171T (pt) 2005-05-18 2022-06-30 Morphosys Ag Anticorpos anti-gm-csf e suas utilizações
BRPI0611220A2 (pt) 2005-06-02 2010-08-24 Astrazeneca Ab anticorpos direcionados para cd20 e usos dos mesmos
BRPI0613783A2 (pt) * 2005-07-18 2011-02-01 Bipar Sciences Inc tratamento de cáncer
EP1917030A4 (en) 2005-08-03 2011-03-09 Immunogen Inc IMMUNKONJUGATFORMULIERUNGEN
US20090306101A1 (en) * 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
EP1951305A1 (en) 2005-11-22 2008-08-06 Wyeth a Corporation of the State of Delaware Immunoglobulin fusion protein formulations
EP1854478A1 (en) 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
US8128926B2 (en) * 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
BRPI0816014A8 (pt) 2007-10-01 2018-06-19 Bristol Myers Squibb Co anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina
CN101952319B (zh) 2007-11-26 2015-04-15 拜耳知识产权有限责任公司 抗-间皮素抗体及其用途
WO2009134977A1 (en) * 2008-04-30 2009-11-05 Immunogen, Inc. Cross-linkers and their uses
US20090298088A1 (en) * 2008-05-30 2009-12-03 Belyaev Alexander S Cleavable catalytic binding and detection system
MX2010013833A (es) * 2008-06-16 2011-02-15 Immunogen Inc Nuevos efectos sinergisticos.
BRPI0916668B1 (pt) * 2008-08-05 2021-12-28 Novartis Ag Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
MX2011009312A (es) 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
AU2010230063B2 (en) * 2009-03-24 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
RU2595424C2 (ru) * 2009-06-03 2016-08-27 Иммьюноджен, Инк. Способы конъюгации
WO2012143497A2 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
HRP20191053T1 (hr) 2013-10-25 2019-09-20 Bayer Pharma Aktiengesellschaft Nova stabilna formulacija

Also Published As

Publication number Publication date
CR20110566A (es) 2012-02-20
TN2011000547A1 (en) 2013-05-24
GT201100269A (es) 2013-08-21
KR20120031265A (ko) 2012-04-02
EP3292874B1 (en) 2020-04-08
NO2424569T3 (es) 2018-03-17
CO6450601A2 (es) 2012-05-31
RU2011148220A (ru) 2013-06-10
CY1123165T1 (el) 2021-10-29
WO2010124797A1 (en) 2010-11-04
LT2424569T (lt) 2018-02-12
AR076284A1 (es) 2011-06-01
HK1170671A1 (zh) 2013-03-08
TW201529084A (zh) 2015-08-01
MX2011011365A (es) 2012-09-28
ECSP11011423A (es) 2011-11-30
IL215769A0 (en) 2012-01-31
ES2655273T3 (es) 2018-02-19
JP5616433B2 (ja) 2014-10-29
UY32560A (es) 2010-11-30
KR101681795B1 (ko) 2016-12-01
HRP20180015T1 (hr) 2018-02-09
HRP20200884T1 (hr) 2020-09-04
AU2010243942B2 (en) 2015-01-29
MY158624A (en) 2016-10-31
EP3292874A1 (en) 2018-03-14
BRPI1014637A2 (pt) 2019-04-16
PT3292874T (pt) 2020-05-15
BRPI1014637B1 (pt) 2021-08-24
TW201105351A (en) 2011-02-16
US20180201690A1 (en) 2018-07-19
JP6395783B2 (ja) 2018-09-26
HUE037853T2 (hu) 2018-09-28
EP2424569A1 (en) 2012-03-07
CN102458477B (zh) 2016-08-24
DK2424569T3 (en) 2018-01-15
ES2790732T3 (es) 2020-10-29
SI2424569T1 (en) 2018-02-28
CU20110200A7 (es) 2012-06-21
HUE049795T2 (hu) 2020-10-28
UA116874C2 (uk) 2018-05-25
IL215769A (en) 2016-12-29
US20170327589A1 (en) 2017-11-16
US10647779B2 (en) 2020-05-12
US20200377614A1 (en) 2020-12-03
US20150322160A1 (en) 2015-11-12
SG175254A1 (en) 2011-11-28
CL2011002681A1 (es) 2012-07-13
AU2010243942A8 (en) 2012-06-07
CN106177984A (zh) 2016-12-07
ZA201107757B (en) 2012-12-27
CA2760114C (en) 2017-11-21
UA106492C2 (uk) 2014-09-10
LT3292874T (lt) 2020-06-10
PT2424569T (pt) 2018-01-11
AU2010243942A1 (en) 2011-11-10
JP2012525342A (ja) 2012-10-22
CU23929B1 (es) 2013-07-31
NZ596013A (en) 2013-11-29
TWI472343B (zh) 2015-02-11
US10781263B2 (en) 2020-09-22
JP2017039735A (ja) 2017-02-23
CY1119738T1 (el) 2018-06-27
SI3292874T1 (sl) 2020-07-31
CN106177984B (zh) 2019-12-24
WO2010124797A8 (en) 2011-12-08
DOP2011000331A (es) 2011-11-15
DK3292874T3 (da) 2020-06-02
CN102458477A (zh) 2012-05-16
JP2015042174A (ja) 2015-03-05
PL3292874T3 (pl) 2020-10-19
JO3486B1 (ar) 2020-07-05
MA33229B1 (fr) 2012-04-02
PE20120556A1 (es) 2012-05-09
PL2424569T3 (pl) 2018-03-30
CA2760114A1 (en) 2010-11-04
EP2424569B1 (en) 2017-10-18
US9084829B2 (en) 2015-07-21
US20120189644A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
HN2011002834A (es) Inmunoconjugados de antimesotelina y usos de los mismos
PE20200152A1 (es) Receptores de union a antigeno mejorados
CL2018001971A1 (es) Ror1 composiciones de anticuerpos y métodos relacionados
DOP2020000032A (es) Proteínas de unión específicas y sus usos
PE20090245A1 (es) Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
CL2019003050A1 (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinación.
AR096015A1 (es) Conjugados de fármacos con anticuerpos
CL2018002383A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmunológicamente activos de los mismos y sus usos. (divisional solicitud 201202433)
AR080301A1 (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
AR095666A1 (es) Conjugados de fármacos con anticuerpos
UY35173A (es) Proteínas de unión al antígeno bcma
UY32915A (es) Proteínas de únión específicas y sus usos
CL2019001745A1 (es) Conjugados anticuerpo droga para ablacion de celulas madre hematopoyeticas.
CL2019001129A1 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y.
CL2012000806A1 (es) Anticuerpo anti-guanililo ciclasa c (gcc); inmunoconjugado de dicho anticuerpo; celula, vector y metodo de produccion; composicion que comprende el anticuerpo, uso del anticuerpo o composicion para preparar un medicamento para tratar cancer, particularmente del sistema gastrointestinal.
MX2020007077A (es) Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
AR119346A1 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
AR071304A1 (es) Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer
AR122052A2 (es) Anticuerpos terapéuticos y sus usos
AR116616A1 (es) Variantes de anticuerpo anti-lap y usos de las mismas
AR107431A1 (es) Anticuerpos específicos contra la variante iii del receptor del factor de crecimiento epidérmico y sus usos
AR114222A1 (es) Métodos de uso para células t con receptor de antígeno quimérico (car)
CU24558B1 (es) Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados
AR110397A1 (es) Conjugados de medicamento-anticuerpo para la ablación de células madre hematopoyéticas